Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00088933
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00003810
- Locations
- 🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT00004264
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Docetaxel in Treating Patients With Stage IV Prostate Cancer
- Conditions
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00003781
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00004164
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT00086957
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Hematology Oncology Consultants-Hemet, Hemet, California, United States
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00087035
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 22
- Registration Number
- NCT00087165
- Locations
- 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
🇨🇦British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 106
- Registration Number
- NCT00003762
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸CCOP - Geisinger Clinical and Medical Center, Danville, Pennsylvania, United States
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00084435
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Grant Riverside Cancer Services, Columbus, Ohio, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.